Cortexyme is a biopharmaceutical company that is focused on developing innovative therapies for patients with Alzheimer's disease and other degenerative diseases. The company's lead therapeutic candidate, atuzaginstat (COR388), is currently being studied in an ongoing Phase 2/3 clinical trial for patients with mild to moderate Alzheimer's disease. Cortexyme is targeting a specific infectious pathogen found in the brain of Alzheimer's patients, which is linked to neurodegeneration and neuroinflammation in animal models. The company's approach represents a promising breakthrough in the treatment of Alzheimer's disease and other neurodegenerative disorders.
Cortexyme, Inc.'s ticker is CRTX
The company's shares trade on the NASDAQ stock exchange
They are based in South San Francisco, California
There are 11-50 employees working at Cortexyme, Inc.
It is https://www.cortexyme.com/
Cortexyme, Inc. is in the Healthcare sector
Cortexyme, Inc. is in the Biotechnology industry
The following five companies are Cortexyme, Inc.'s industry peers: